Literature DB >> 22023067

Savings from the use of a probiotic formula in the prophylaxis of antibiotic-associated diarrhea.

Alvine Adrienne Kamdeu Fansi1, Jason Robert Guertin, Jacques LeLorier.   

Abstract

OBJECTIVE: Antibiotic-associated diarrhea (AAD) and particularly Clostridium difficile-associated diarrhea (CDAD) are the most common causes of healthcare associated infectious diarrhea. A double-blind, dose response, placebo-controlled trial of the probiotic formula (Bio-K+ Lactobacillus acidophilus CL1285 and Lactobacillus casei LBC80R formula) for prophylaxis of AAD and CDAD was published in 2010. The Bio-K+ Lactobacillus acidophilus CL1285 and Lactobacillus casei LBC80R formula is a registered trademark of Bio-K Plus International Inc. (Laval, Québec, Canada). Results indicated that the incidence of AAD and CDAD were lower for patients assigned to the probiotic formula compared with the placebo option. The present study aims to estimate the savings in direct medical costs that might result from the use of two different doses of the probiotic formula vs placebo.
METHODS: A cost-consequence analysis was conducted to compare the two doses of the probiotic formula compared to placebo. The analysis was based upon published data and adjusted to the North American context.
RESULTS: Economic analyses showed that the use of the probiotic formula would result in estimated mean per patients savings of US$1968 for the single dose and US$2661 for the double dose compared with the placebo option if used an average of 13 days by all patients at risk of developing AAD and CDAD. LIMITATIONS: Several key parameters considered within the economic model were not captured within the Gao et al. study. Numerous sensitivity analyses were conducted to address this issue.
CONCLUSION: The use of the probiotic formula in prophylaxis of AAD and CDAD would lead to estimated savings in direct medical costs that would substantially offset its acquisition cost. Treating 1000 hospitalized patients on antibiotics with the double dose of the product compared to current practice would save a single payer system the sum of $2,661,218.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22023067     DOI: 10.3111/13696998.2011.629015

Source DB:  PubMed          Journal:  J Med Econ        ISSN: 1369-6998            Impact factor:   2.448


  6 in total

Review 1.  Probiotics in Helicobacter pylori eradication therapy: a systematic review and meta-analysis.

Authors:  Min-Min Zhang; Wei Qian; Ying-Yi Qin; Jia He; Yu-Hao Zhou
Journal:  World J Gastroenterol       Date:  2015-04-14       Impact factor: 5.742

Review 2.  Probiotics in dietary guidelines and clinical recommendations outside the European Union.

Authors:  Stephan Ebner; Linda N Smug; Wolfgang Kneifel; Seppo J Salminen; Mary Ellen Sanders
Journal:  World J Gastroenterol       Date:  2014-11-21       Impact factor: 5.742

Review 3.  Comparison of pediatric and adult antibiotic-associated diarrhea and Clostridium difficile infections.

Authors:  Lynne Vernice McFarland; Metehan Ozen; Ener Cagri Dinleyici; Shan Goh
Journal:  World J Gastroenterol       Date:  2016-03-21       Impact factor: 5.742

4.  Probiotics use for antibiotic-associated diarrhea: a pragmatic participatory evaluation in nursing homes.

Authors:  Herman A van Wietmarschen; Martine Busch; Annemiek van Oostveen; Gerda Pot; Miek C Jong
Journal:  BMC Gastroenterol       Date:  2020-05-13       Impact factor: 3.067

5.  Probiotics in hospitalized adult patients: a systematic review of economic evaluations.

Authors:  Vincent I Lau; Bram Rochwerg; Feng Xie; Jennie Johnstone; John Basmaji; Jana Balakumaran; Alla Iansavichene; Deborah J Cook
Journal:  Can J Anaesth       Date:  2019-11-12       Impact factor: 5.063

6.  Cost-benefit relation of diet and probiotics in iatrogenic bowel irregularity (IBI).

Authors:  Eric Claassen
Journal:  Front Pharmacol       Date:  2014-02-17       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.